LTS13769 -GZ402666 (Phase 2/3 klinische Studie)
Laufzeit: 01.01.2019 - 31.12.2021
Kurzfassung
An open, multicentre, international, long-term study on the safety and pharmacokinetics of fortnightly repeated infusions of neoGAA in patients with Pompe disease
